SynthesisFrontiers in immunology2026
Performance of Tai Chi Chuan and NF-κB-driven proinflammatory gene expression (IL-6, IL-1β, TNF-α) in adult chronic disease patients: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reflections on 20 Years of Research on Tai Chi for Chronic Musculoskeletal Pain: An Updated Review.Current rheumatology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review and meta-analysis aims to evaluate the effects of Tai Chi Chuan on the expression of pro-inflammatory genes IL-6, IL-1β, and TNF-α-downstream of the NF-κB pathway-in adults with chronic diseases. It further explores potential anti-inflammatory mechanisms and identifies research gaps in the literature regarding these mechanisms. Methods: This study searched seven electronic databases for relevant literature, with language restrictions limited to English and Chinese. The risk of bias in all included trials was assessed using the Cochrane Risk of Bias Assessment Tool (version 2.0) and the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system. Standardized mean differences (SMD) with 95% confidence intervals (CI) were used to evaluate pooled effect sizes. P values < 0.05 were considered statistically significant. Subgroup analyses were conducted according to disease systems. Results: We retrieved a total of 1,110 relevant studies, with 20 studies ultimately included in the analysis. These covered diseases across multiple systems, including oncology, endocrinology, respiratory, and neurological disorders. To more directly reflect intervention effects, we extracted the mean ± standard deviation of change values post-intervention compared to baseline as the analysis data. After assessing publication bias and minimizing heterogeneity effects, we found that Tai Chi Chuan significantly reduced the expression of downstream target genes (SMD = -0.48, 95% CI: -0.76 to -0.19, p < 0.01), significantly down-regulated IL-6 (SMD = -0.66, 95% CI: -1.27 to -0.06, p = 0.03), and IL-1β (SMD = -0.59, 95% CI: -0.95 to -0.23, p < 0.01). while TNF-α showed a downward trend but without statistical significance (SMD = -0.28, 95% CI: -0.59 to 0.02, p = 0.07). Subgroup analysis revealed that patients with endocrine and respiratory system diseases derived the most significant benefit. Conclusion: Tai Chi can alleviate systemic inflammation in patients with chronic diseases by suppressing NF-κB-driven pro-inflammatory gene expression, demonstrating both safety and feasibility. Furthermore, we identified gaps in existing research on Tai Chi and NF-κB, particularly the lack of randomized controlled trials (RCTs). Future studies should conduct RCTs with NF-κB core proteins and factors as direct outcome measures to directly elucidate Tai Chi's regulatory effects on the NF-κB pathway. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251112908.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.